Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) surged +1.46% and closed the trade at $ 408.63. The company recorded a trading capacity of 1.31 million shares above its three months average daily volume of 813.96 thousand shares. During the last trade, shares reached to high price of $411.00 and touched the low price of $400.37. The stock’s 50-day moving average is noted at $410.57 and its 200-day moving average is stands at $389.43.
Additionally, the company has a PE ratio of 63.75 and has EPS of 6.41. The company has market capitalization of $42.76B.
Currently Regeneron Pharmaceuticals, Inc. (REGN) captured an average recommendation of “ Overweight ” from analysts, according to FactSet data. The stock has been suggested as “Buy” from “11″ Analysts”. “1” rated “Sell” for the company. “13” said the company as a “Hold”. Overweight rating was given by “2” and Underweight rating was given by “0”.
Analysts are expecting that the company to achieve $468.87 Price Target in next 52-weeks, average price is come up through the consensus of analysts. High potential price target is set at $648.00 however minimum price target advised by analysts is $325.00. The Median price target for the stock is measured at $465.00.
Presently, Analysts decided consensus EPS estimate of $2.72 for present quarter and one month ago projected EPS estimate was at $2.72. If we take a look at back 3 month ago, consensus EPS estimate was $2.80.
A current consensus EPS estimate for next quarter is at $2.78 and 3 month ago EPS forecast was $2.89. Have a look at back 1 month ago, consensus EPS forecast was seen at $2.78.
For current fiscal year, most recent EPS estimate is set at $10.94 based on Analyst consensus and three month ago consensus EPS opinions was at $10.86. During period one month ago, consensus EPS forecast was decided at $10.91.
A current consensus EPS projection for next fiscal year is observed at $14.80 and one month ago consensus EPS forecast was at $14.37. Take a look at back three month ago, consensus EPS estimate opinions was decided at $15.42 by analysts.
One Month ago, the stock has gained consensus mean rating of Overweight based on the analysis of brokerage analyst firms polled. 11 presented the recommendations about the stock as a “Buy” signal and “Overweight” signal was reported by 2. 13 advised the “Hold” rating about this stock. 1 revealed “Sell” signal and “Underweight” rating was declared by 0.
Three Months Ago, Analysts recommended an average brokerage rating of Overweight derived from brokerage firms, according to FactSet. 12 said a “Buy Rating” and 2 announced “Overweight Rating”. 12 advised “Hold Rating” regarding the stock. 1 announced “Sell Rating” and 0 disclosed “Underweight Rating”.